AGN — Argenica Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- AU$14.77m
- AU$8.41m
- AU$0.21m
Annual balance sheet for Argenica Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 8.91 | 9.29 | 15.9 | 10.6 | 6.36 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.072 | 0.152 | 0.372 | 0.421 | 0.097 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 9.04 | 9.54 | 16.4 | 11 | 6.52 |
| Net Intangible Assets | |||||
| Total Assets | 9.04 | 9.54 | 16.4 | 11 | 6.52 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.736 | 1.87 | 2.43 | 3.8 | 0.615 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.736 | 1.87 | 2.43 | 3.8 | 0.615 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 8.31 | 7.67 | 14 | 7.24 | 5.9 |
| Total Liabilities & Shareholders' Equity | 9.04 | 9.54 | 16.4 | 11 | 6.52 |
| Total Common Shares Outstanding |